EnVVeno Medical Unveils Recap Website from 2024 VEITH Symposium

enVVeno Medical Corporation, a company dedicated to advancing care for venous diseases, has launched a recap website showcasing its participation in the 51st Annual VEITH Symposium. The site includes interviews with patients and principal investigators from the VenoValve® U.S. Pivotal Trial, along with data presented at the event.

CEO Robert Berman emphasized the value of firsthand accounts from both physicians and patients, noting their crucial role in the company's commercial efforts post-FDA approval. VenoValve®, a potential first-in-class surgical valve for severe CVI, may benefit millions in the U.S. annually.

Severe CVI, often caused by deep vein thromboses, has significant impacts on daily life and healthcare costs. enVVeno is also developing enVVe®, a next-generation valve, for broader market appeal.